{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031139","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.596607+00:00","generated_at":"2026-06-22T00:36:07.351392+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"GT Biopharma adopts amended bylaws with proxy access and exclusive forum provisions","bullets":["Amended bylaws effective Nov 3, 2022 include proxy access for eligible long-term shareholders.","Updated advance notice requirements for director nominations and shareholder proposals.","Added exclusive forum provision for certain legal actions.","Clarified authority to adjourn shareholder meetings when quorum not present."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031139","json":"https://secwatch.observer/filing/0001493152-22-031139.json","markdown":"https://secwatch.observer/filing/0001493152-22-031139.md","text":"https://secwatch.observer/filing/0001493152-22-031139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/0001493152-22-031139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:36:07.351392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7aba5e9fc85b136e2045338747f452310519d5fb","claim":"GT Biopharma, Inc.: Amended and restated bylaws to update procedures, including shareholder meetings, advance notice requirements, proxy access, and exclusive forum provision (effective 2022-11-03).","evidence_excerpt":"On November 3, 2022, the Board of Directors of GT Biopharma, Inc. (the “Company”) amended and restated the Company’s Restated Bylaws (the “Amended Bylaws”) to update certain procedures and make various technical and conforming changes.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/0001493152-22-031139-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-11-03"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}